Skip to main content
SpringerLink
Log in

Strategies for the Management of Patients with Obesity

  • Therapy In Practice
  • Published:
Treatments in Endocrinology

Abstract

The prevalence of overweight and obesity is increasing worldwide. During the last two decades, the prevalence of adults in the higher body mass index (BMI) categories in the US has increased the most, as much as 300% for those with a BMI above 40kg/m2. In children and adolescents, a doubling of the prevalence of severe overweight poses a serious health risk to future generations of young adults who may develop chronic diseases normally associated with aging.

The simple definition of obesity, an imbalance between energy intake and energy expenditure, ignores the complexity of, and largely unknown interactions between, genes, food intake and physical activity, which together determine bodyweight and fat distribution.

Although the etiology and manifestations of overweight and obesity are complex, the assessment of overweight and obesity requires only an accurate measurement of bodyweight, height and abdominal circumference, as well as a history and physical examination attuned to the morbidities that commonly accompany overweight and obesity such as diabetes mellitus, hypertension, dyslipidemia and sleep apnea.

The treatment of patients with overweight and obesity continues to be based on changes to diet and physical activity. Simple behavior modification techniques are within the reach of busy clinicians. The additional use of available bodyweight reduction medications can reliably lead to a 5 to 10% reduction from initial bodyweight, a loss that has been shown to provide significant health benefit. The use of meal replacements has also been shown to be effective and is probably an under-appreciated treatment resource. Surgery is the most successful treatment for those with severe obesity and should be discussed as an option for those in the appropriate bodyweight categories.

Because societal trends favor the greater intake of calorie-dense foods and less physical activity to accomplish the activities of daily life, the future of obesity treatment will require the development of bodyweight reduction medications that work by a variety of mechanisms to decrease food intake or increase energy expenditure. Such medications should not be viewed as a ‘crutch’ but rather as a ‘helping hand’ that enable people to better adhere to a healthier lifestyle.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII

Similar content being viewed by others

References

  1. Gallagher D, Visser M, Sepulveda D, et al. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol 1996; 143(3): 228–39

    Article  PubMed  CAS  Google Scholar 

  2. Stevens J. Obesity and mortality in Africans-Americans. Nutr Rev 2000; 58(11): 346–53

    Article  PubMed  CAS  Google Scholar 

  3. Park YW, Allison DB, Heymsfield SB, et al. Larger amounts of visceral adipose tissue in Asian Americans. Obes Res 2001; 9(7): 381–7

    Article  PubMed  CAS  Google Scholar 

  4. Gallagher D, Heymsfield SB, Heo M, et al. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr 2000; 72(3): 694–701

    PubMed  CAS  Google Scholar 

  5. Deurenberg P. Universal cut-off BMI points for obesity are not appropriate. Br J Nutr 2001; 85(2): 135–6

    Article  PubMed  CAS  Google Scholar 

  6. Obesity: preventing and managing the global epidemic. World Health Organization; 1997 Jun 3–5; Geneva. Geneva: WHO, 1998.

  7. Lapidus L, Bengtsson C, Larsson B, et al. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. BMJ (Clin Res Ed) 1984; 289(6454): 1257–61

    Article  CAS  Google Scholar 

  8. Larsson B, Svardsudd K, Welin L, et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. BMJ (Clin Res Ed) 1984; 288(6428): 1401–4

    Article  CAS  Google Scholar 

  9. Lemieux S, Prud’homme D, Bouchard C, et al. A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 1996; 64(5): 685–93

    PubMed  CAS  Google Scholar 

  10. Fujioka S, Matsuzawa Y, Tokunaga K, et al. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987; 36(1): 54–9

    Article  PubMed  CAS  Google Scholar 

  11. North American Association for the Study of Obesity. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. Washington, DC: National Institutes of Health. National Heart, Lung, and Blood Institute, 2000 Oct: 1-77 (NIH Publication No. 00-4084)

    Google Scholar 

  12. Smith SR, Lovejoy JC, Greenway F, et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism 2001; 50(4): 425–35

    Article  PubMed  CAS  Google Scholar 

  13. Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord 1998; 22(1): 39–47

    Article  PubMed  CAS  Google Scholar 

  14. Mokdad AH, Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the United States, 1991–1998. JAMA 1999; 282(16): 1519–22

    Article  PubMed  CAS  Google Scholar 

  15. Styne DM. Childhood and adolescent obesity. Prevalence and significance. Pediatr Clin North Am 2001; 48(4): 823–54, vii

    Article  PubMed  CAS  Google Scholar 

  16. Flegal KM, Troiano RP. Changes in the distribution of body mass index of adults and children in the US population. Int J Obes Relat Metab Disord 2000; 24(7): 807–18

    Article  PubMed  CAS  Google Scholar 

  17. Williams S. Overweight at age 21: the association with body mass index in childhood and adolescence and parents’ body mass index. A cohort study of New Zealanders born in 1972–1973. Int J Obes Relat Metab Disord 2001; 25(2): 158–63

    Article  PubMed  CAS  Google Scholar 

  18. Perusse L, Bouchard C. Genotype-environment interaction in human obesity. Nutr Rev 1999; 57 (5 Pt 2): S31–7; discussion S37-8

    Article  PubMed  CAS  Google Scholar 

  19. Bouchard C, Perusse L, Leblanc C, et al. Inheritance of the amount and distribution of human body fat. Int J Obes 1988; 12(3): 205–15

    PubMed  CAS  Google Scholar 

  20. Stunkard AJ, Sorensen TI, Hanis C, et al. An adoption study of human obesity. N Engl J Med 1986; 314(4): 193–8

    Article  PubMed  CAS  Google Scholar 

  21. Perusse L, Bouchard C. Genetics of energy intake and food preferences. In: Bouchard C, editor. The genetics of obesity. Boca Raton (FL): CRC Press, 1994:125–34

    Google Scholar 

  22. Perusse L, Tremblay A, Leblanc C, et al. Genetic and environmental influences on level of habitual physical activity and exercise participation. Am J Epidemiol 1989; 129(5): 1012–22

    PubMed  CAS  Google Scholar 

  23. Hebebrand J, Sommerlad C, Geller F, et al. The genetics of obesity: practical implications. Int J Obes Relat Metab Disord 2001; 25Suppl. 1: S10–8

    Article  PubMed  CAS  Google Scholar 

  24. Perusse L, Chagnon YC, Weisnagel SJ, et al. The human obesity gene map: the 2000 update. Obes Res 2001; 9(2): 135–69

    Article  PubMed  CAS  Google Scholar 

  25. Lichtenstein AH, Kennedy E, Barrier P, et al. Dietary fat consumption and health. Nutr Rev 1998; 56 (5 Pt 2): S3–19; discussion S19-28

    Article  PubMed  CAS  Google Scholar 

  26. James WP. A public health approach to the problem of obesity. Int J Obes Relat Metab Disord 1995; 19Suppl. 3: S37–45

    PubMed  Google Scholar 

  27. Heitmann BL, Lissner L, Osier M. Do we eat less fat, or just report so? Int J Obes Relat Metab Disord 2000; 24(4): 435–42

    Article  PubMed  CAS  Google Scholar 

  28. Poppitt SD, Swann D, Black AE, et al. Assessment of selective under-reporting of food intake by both obese and non-obese women in a metabolic facility. Int J Obes Relat Metab Disord 1998; 22(4): 303–11

    Article  PubMed  CAS  Google Scholar 

  29. Bray GA, Popkin BM. Dietary fat affects obesity rate. Am J Clin Nutr 1999; 70(4): 572–3

    PubMed  CAS  Google Scholar 

  30. Martinez JA. Body-weight regulation: causes of obesity. Proc Nutr Soc 2000; 59(3): 337–45

    Article  PubMed  CAS  Google Scholar 

  31. Zurlo F, Ferraro RT, Fontvielle AM, et al. Spontaneous physical activity and obesity: cross-sectional and longitudinal studies in Pima Indians. Am J Physiol 1992; 263 (2 Pt 1): E296–300

    PubMed  CAS  Google Scholar 

  32. Levine JA, Eberhardt NL, Jensen MD. Role of nonexercise activity thermogenesis in resistance to fat gain in humans. Science 1999; 283(5399): 212–4

    Article  PubMed  CAS  Google Scholar 

  33. Sugerman HJ. Effects of increased intra-abdominal pressure in severe obesity. Surg Clin North Am 2001; 81(5): 1063–75, vi

    Article  PubMed  CAS  Google Scholar 

  34. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998; 22(12): 1145–58

    Article  PubMed  CAS  Google Scholar 

  35. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999; 100(1): 96–102

    Article  PubMed  CAS  Google Scholar 

  36. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409(6818): 307–12

    Article  PubMed  CAS  Google Scholar 

  37. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. 1956. Obes Res 1996; 4(2): 204–12

    PubMed  CAS  Google Scholar 

  38. Grundy SM. Metabolic complications of obesity. Endocrine 2000; 13(2): 155–65

    Article  PubMed  CAS  Google Scholar 

  39. Brands MW, Hall JE, Keen HL. Is insulin resistance linked to hypertension? Clin Exp Pharmacol Physiol 1998; 25(1): 70–6

    Article  PubMed  CAS  Google Scholar 

  40. Sheehan MT, Jensen MD. Metabolic complications of obesity. Pathophysiologic considerations. Med Clin North Am 2000; 84(2): 363–85, vi

    Article  PubMed  CAS  Google Scholar 

  41. Despres JP. Obesity and lipoprotein metabolism. In: Bray GA, Bouchard C, editors. Handbook of obesity. New York: Marcel Dekker, 1998: 651–675

    Google Scholar 

  42. Hubler A, Abendroth K, Keiner T, et al. Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence Syndrome) connected with autoantibodies against adipocyte membranes. Exp Clin Endocrinol Diabetes 1998; 106(1): 79–84

    Article  PubMed  CAS  Google Scholar 

  43. Robbins DC, Horton ES, Tulp O, et al. Familial partial lipodystrophy: complications of obesity in the non-obese? Metabolism 1982; 31(5): 445–52

    Article  PubMed  CAS  Google Scholar 

  44. Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000; 105(3): 271–8

    Article  PubMed  CAS  Google Scholar 

  45. Hallakou S, Doare L, Foufelle F, et al. Pioglitazone induced in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 1997; 46(9): 1393–9

    Article  PubMed  CAS  Google Scholar 

  46. Smith SR, Ravussin E. Emerging paradigms for understanding fatness and diabetes risk. Curr Diabetes Rep. In press

  47. Stunkard AJ, Wadden TA. Psychological aspects of severe obesity. Am J Clin Nutr 1992; 55(2 Suppl.): 524S–32S

    PubMed  CAS  Google Scholar 

  48. Hill AJ, Silver EK. Fat, friendless and unhealthy: 9-year old children’s perception of body shape stereotypes. Int J Obes Relat Metab Disord 1995; 19(6): 423–30

    PubMed  CAS  Google Scholar 

  49. Puhl R, Brownell K. Obesity, bias and discrimination. Obes Res 2001; 9(12): 788–805

    Article  PubMed  CAS  Google Scholar 

  50. Rand CS, Macgregor AM. Morbidly obese patients’ perceptions of social discrimination before and after surgery for obesity. South Med J 1990; 83(12): 1390–5

    Article  PubMed  CAS  Google Scholar 

  51. Gortmaker SL, Must A, Perrin JM, et al. Social and economic consequences of overweight in adolescence and young adulthood. N Engl J Med 1993; 329(14): 1008–12

    Article  PubMed  CAS  Google Scholar 

  52. Colditz GA. Economic costs of obesity and inactivity. Med Sci Sports Exerc 1999; 31(11 Suppl.): S663–7

    PubMed  CAS  Google Scholar 

  53. Thompson D, Brown JB, Nichols GA, et al. Body mass index and future healthcare costs: a retrospective cohort study. Obes Res 2001; 9(3): 210–8

    Article  PubMed  CAS  Google Scholar 

  54. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61(Suppl. 11): 37–41

    PubMed  CAS  Google Scholar 

  55. Adams CH, Smith NJ, Wilbur DC, et al. The relationship of obesity to the frequency of pelvic examinations: do physician and patient attitudes make a difference? Women Health 1993; 20(2): 45–57

    Article  PubMed  CAS  Google Scholar 

  56. Institute of Medicine. Weighing the options. Washington, DC: National Academy Press, 1995

    Google Scholar 

  57. Blackburn G. Effect of degree of weight loss on health benefits. Obes Res 1995; 3Suppl. 2: 211–6

    Google Scholar 

  58. Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am 2000; 84(2): 441–61, vii

    Article  PubMed  CAS  Google Scholar 

  59. Brownell K. The learn program for weight management. Dallas (TX): American Health Publishing Company, 2000

    Google Scholar 

  60. Crowther JH, Sanftner J, Bonifazi DZ, et al. The role of daily hassles in binge eating. Int J Eat Disord 2001; 29(4): 449–54

    Article  PubMed  CAS  Google Scholar 

  61. Epel E, Lapidus R, McEwen B, et al. Stress may add bite to appetite in women: a laboratory study of stress-induced cortisol and eating behavior. Psychoneuro-endocrinology 2001; 26(1): 37–49

    Article  CAS  Google Scholar 

  62. Ditschuneit HH, Flechtner-Mors M, Johnson TD, et al. Metabolic and weight-loss effects of a long-term dietary intervention in obese patients. Am J Clin Nutr 1999; 69(2): 198–204

    PubMed  CAS  Google Scholar 

  63. Freedman MR, King J, Kennedy E. Popular diets: a scientific review. Obes Res 2001; 9Suppl. 1: 1–40

    Article  Google Scholar 

  64. Astrup A, Grunwald GK, Melanson EL, et al. The role of low-fat diets in body weight control: a meta-analysis of ad libitum dietary intervention studies. Int J Obes Relat Metab Disord 2000; 24(12): 1545–52

    Article  PubMed  CAS  Google Scholar 

  65. Astrup A, Ryan L, Grunwald GK, et al. The role of dietary fat in body fatness: evidence from a preliminary meta-analysis of ad libitum low-fat dietary intervention studies. Br J Nutr 2000; 83 Suppl. 1: 25–32

    Google Scholar 

  66. Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr 2001; 21: 323–41

    Article  PubMed  CAS  Google Scholar 

  67. Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. JAMA 1996; 276(3): 241–6

    Article  Google Scholar 

  68. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther 1992; 51(5): 642–6

    Article  PubMed  CAS  Google Scholar 

  69. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337(9): 581–8

    Article  PubMed  CAS  Google Scholar 

  70. Burger AJ, Sherman HB, Charlamb MJ, et al. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol 1999; 34(4): 1153–8

    Article  PubMed  CAS  Google Scholar 

  71. Mast ST, Jollis JG, Ryan T, et al. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001; 134(4): 261–6

    PubMed  CAS  Google Scholar 

  72. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000; 248(3): 245–54

    Article  PubMed  CAS  Google Scholar 

  73. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286(11): 1331–9

    Article  PubMed  CAS  Google Scholar 

  74. Astrup A, Breum L, Toubros S, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: a double blind trial. Int J Obes Relat Metab Disord 1992; 16: 269–77

    PubMed  CAS  Google Scholar 

  75. Astrup A, Toubros S, Cannon S, et al. Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study. Metabolism 1991; 40: 323–9

    Article  PubMed  CAS  Google Scholar 

  76. Dulloo AG, Seydoux J, Girardier L. Potentiation of the thermogenic antiobesity effects of ephidrine by dietary methylaxanthines: adenosine antagonism or phosphodiestrerase inhibition. Metabolism 1992; 41: 1233–41

    Article  PubMed  CAS  Google Scholar 

  77. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20(6): 805–75

    Article  PubMed  CAS  Google Scholar 

  78. Munro JF, MacCuish AC, Wilson EM, et al. Comparison of continuous and intermittent anorectic therapy in obesity. BMJ 1968; 1: 352–6

    Article  PubMed  CAS  Google Scholar 

  79. Physicians’ desk reference. 56th ed. Montevale (NJ), United States: Medical Economics Co., 2002

  80. Langlois KJ, Forbes JA, Bell GW, et al. A double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity. Curr Ther Res Clin Exp 1974; 16(4): 289–96

    PubMed  CAS  Google Scholar 

  81. Williams RA, Foulsham BM. Weight reduction in osteoarthritis using phentermine. Practitioner 1981; 225: 231–2

    Google Scholar 

  82. Rolls BJ, Shide DJ, Thorwart ML, et al. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998; 6(1): 1–11

    PubMed  CAS  Google Scholar 

  83. Hansen DL, Toubro S, Stock MJ, et al. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999; 23(10): 1016–24

    Article  PubMed  CAS  Google Scholar 

  84. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999; 7(2): 189–98

    PubMed  CAS  Google Scholar 

  85. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001; 50(6): 505–12

    PubMed  CAS  Google Scholar 

  86. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356(9248): 2119–25

    CAS  Google Scholar 

  87. Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000; 2(3): 175–87

    Article  PubMed  CAS  Google Scholar 

  88. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160(14): 2185–91

    Article  PubMed  CAS  Google Scholar 

  89. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352(9123): 167–72

    Article  PubMed  CAS  Google Scholar 

  90. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281(3): 235–42

    Article  PubMed  CAS  Google Scholar 

  91. Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord 2001; 25(7): 1095–9

    Article  PubMed  CAS  Google Scholar 

  92. Drent ML, van der Veen EA. First clinical studies with orlistat: a short review. Obes Res 1995 Nov; 3 Suppl. 4: 623S–5S

    Google Scholar 

  93. Torgerson JS, Sjostrom L. The Swedish Obese Subjects (SOS) study-rationale and results. Int J Obes Relat Metab Disord 2001; 25 Suppl. 1: S2–4

    Article  Google Scholar 

  94. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222(3): 339–50; discussion 350–2

    Article  PubMed  CAS  Google Scholar 

  95. Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Rouxen-Y gastric bypass for morbid obesity. Ann Surg 2000; 232(4): 515–29

    Article  PubMed  CAS  Google Scholar 

  96. Tate DF, Wing RR, Winett RA. Using Internet technology to deliver a behavioral weight loss program. JAMA 2001; 285(9): 1172–7

    Article  PubMed  CAS  Google Scholar 

  97. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: US advance data for vital and health statistics, no. 314. Hyattsville (MD): National Center for Health Statistics, 2000

    Google Scholar 

  98. Cole TJ, Bellizzi MC, Flegal KM, et al. Establishing a standard definition for child overweight and obesity worldwide. BMJ 2000; 320: 1240–3

    Article  PubMed  CAS  Google Scholar 

  99. Ho SC, Chen YM, Woo JL, et al. Association between simple anthropometric indices and cardiovascular risk factors. Int J Obes Relat Metab Disord 2001; 25(11): 1689–97

    Article  PubMed  CAS  Google Scholar 

  100. Blair SN, Cheng Y, Holder JS. Is physical activity or physical fitness more important in defining health benefits? Med Sci Sports Exerc 2001; 33(6 Suppl.): 379–99; discussion 419-20

    Google Scholar 

Download references

Acknowledgements

The author wishes to thank Frank Greenway and Steven Smith for their suggestions and review of this paper and Mary Beth Burnett for her excellent help and organizational skills in the preparation of this manuscript. The author has been a consultant to Medeva, Knoll, Abbott Laboratories and Roche Laboratories and a principal investigator in a clinical trial of orlistat.

Author information

Authors and Affiliations

  1. Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, Louisiana, 70808, USA

    Michael Hamilton

Authors
  1. Michael Hamilton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Hamilton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hamilton, M. Strategies for the Management of Patients with Obesity. Mol Diag Ther 1, 21–36 (2002). https://doi.org/10.2165/00024677-200201010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024677-200201010-00003

Keywords

Search

Navigation